Phase II Neoadjuvant Study of EC followed by Abraxane in opetable breast cancer.

Phase II Neoadjuvant Study of EC followed by Abraxane in opetable breast cancer. - Phase II Neoadjuvant Study of EC followed by Abraxane in opetable breast cancer.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014351

Enrollment

Registered

2014-06-24

Start date

2014-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

EC followed by Abraxane

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)infiltrating primary breast cancer 2)T1-3, N0-2, M0, neoadjuvant setting, operable breast cancer 3)confirmed ER/PgR/HER2 4)20-75 years old, femal 5)measureble lesion(PECIST version 1.1) 6)previously untreated 7)performance status(PS) 0-1 8)maintained organs function: omit 9)informed concent

Exclusion criteria

Exclusion criteria: 1)cardiac dysfunction 2)severe complication(uncontoroled DM, hypertension, renal failure, hepatic failure, severe infection, mental disorder) 3)pregnancy, lactation 4)double cancer 5)bilateral breast cancer 6)pulmonary fibrosis, interstitial pneumonia 7)allergy 8)neuropathy 9)HBs antigen positive

Design outcomes

Primary

Measure	Time frame
pathological complete response (pCR)	—

Countries

Japan

Contacts

Public ContactYutaka Yamamoto

Kawasaki Medical School Breast Thyroid Surgery

yamayou@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026